ROS1-话题@MedSci

#ROS1#

26篇内容 | 2295人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2217555, encodeId=a452221e55516, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a> <a href='/topic/show?id=78aa999190f' target=_blank style='color:#2F92EE;'>#靶向治疗#</a> <a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=为啥基因检测重复做？EGFR/HER2/MET和ROS1变异晚期肺癌治疗长达7年，ROS1融合出现又消失, objectType=article, longId=836883, objectId=8897836883f2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240701/1719800269608_92910.png, objectUrl=/article/show_article.do?id=8897836883f2, replyNumber=0, likeNumber=89, createdTime=2024-07-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8897836883f2, moduleTitle=为啥基因检测重复做？EGFR/HER2/MET和ROS1变异晚期肺癌治疗长达7年，ROS1融合出现又消失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8897836883f2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2182600, encodeId=77172182600e3, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a> <a href='/topic/show?id=42b311026e5f' target=_blank style='color:#2F92EE;'>#瑞波替尼#</a>, objectTitle=NEJM：瑞波替尼在ROS1融合阳性非小细胞肺癌中的应用, objectType=article, longId=809978, objectId=db078099e850, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240118/1705584583628_6145188.png, objectUrl=/article/show_article.do?id=db078099e850, replyNumber=0, likeNumber=91, createdTime=2024-01-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=db078099e850, moduleTitle=NEJM：瑞波替尼在ROS1融合阳性非小细胞肺癌中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db078099e850)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2176666, encodeId=f92721e66660c, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a> <a href='/topic/show?id=4a691563543' target=_blank style='color:#2F92EE;'>#ROS1阳性肺癌#</a> <a href='/topic/show?id=9df42e37593' target=_blank style='color:#2F92EE;'>#信达生物#</a> <a href='/topic/show?id=02c810903654' target=_blank style='color:#2F92EE;'>#泰莱替尼#</a> <a href='/topic/show?id=495f10903e6e' target=_blank style='color:#2F92EE;'>#葆元医药#</a>, objectTitle=新一代强效ROS1抑制剂泰莱替尼（AB-106）获优先审评资格！cORR高达92.5%, objectType=article, longId=806499, objectId=754b80649999, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231222/1703299579204_4754896.jpg, objectUrl=/article/show_article.do?id=754b80649999, replyNumber=0, likeNumber=101, createdTime=2023-12-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=754b80649999, moduleTitle=新一代强效ROS1抑制剂泰莱替尼（AB-106）获优先审评资格！cORR高达92.5%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=754b80649999)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2173456, encodeId=456221e34569a, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a> <a href='/topic/show?id=3ae49e240b5' target=_blank style='color:#2F92EE;'>#间变性淋巴瘤激酶#</a> <a href='/topic/show?id=70b2291294b' target=_blank style='color:#2F92EE;'>#免疫组织化学#</a> <a href='/topic/show?id=e01a8e24227' target=_blank style='color:#2F92EE;'>#荧光原位杂交#</a>, objectTitle=ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE：免疫组织化学和荧光原位杂交在检测非小细胞肺癌中间变性淋巴瘤激酶和ROS1基因重组方面的一致性, objectType=article, longId=803975, objectId=1b078039e56b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202301015/1697393424174_4754896.jpeg, objectUrl=/article/show_article.do?id=1b078039e56b, replyNumber=0, likeNumber=118, createdTime=2023-12-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1b078039e56b, moduleTitle=ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE：免疫组织化学和荧光原位杂交在检测非小细胞肺癌中间变性淋巴瘤激酶和ROS1基因重组方面的一致性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b078039e56b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2094885, encodeId=268c2094885f6, content=在以往的认知里，<a href='/topic/show?id=c40399886f5' target=_blank style='color:#2F92EE;'>#靶向#</a>药、免疫治疗药是特定癌种、特定基因突变、特定靶点、特定通路才能用的药。不少患者基因检测结果没有理想的靶点，失去用药机会，或者尝试跨适应症用药，但跨适应症无法报销或申请赠药。现在，<a href='/topic/show?id=a0c31049e18d' target=_blank style='color:#2F92EE;'>#泛癌种#</a>广谱抗癌药（也称不限癌种的抗肿瘤类药物）的研发成功和上市，给了大家新希望！打破癌种限制让更多患者有药可用！这种不不好用癌种的治疗策略，也被称为“精准治疗”，主要源于<a href='/topic/show?id=5eae41e7007' target=_blank style='color:#2F92EE;'>#基因检测#</a>的结果。根据基因检测的结果，一旦发现对应的靶点，就可以使用某个对应的<a href='/topic/show?id=78aa999190f' target=_blank style='color:#2F92EE;'>#靶向治疗#</a>药物。靶点检测最初从乳腺癌和肺癌比较常见，目前逐步向所有的癌种扩展，包括<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>，<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>等。例如，<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a>患者要检测<a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a></a>、ROS1以及ALK，<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者要检测HER2，胃癌患者要检测HER2。但是，相比起数百种之多的癌症驱动基因，每一类癌症当中，能够被应用于治疗的基因突变还是太少了，远不能满足所有患者的需求。而且目前有靶点的药物的类别也仍然有限，<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a>主要包括PD-1/PD-L1，<a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=4c496569c8' target=_blank style='color:#2F92EE;'>#EGFR#</a></a>，<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>，RET，ALK，MET，BRAF V600E，<a href='/topic/show?id=f5d71312e50' target=_blank style='color:#2F92EE;'>#NTRK#</a>，<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>，<a href='/topic/show?id=13cb1056e20' target=_blank style='color:#2F92EE;'>#KRAS#</a>，MSI-H及dMMR，<a href='/topic/show?id=17a51049e230' target=_blank style='color:#2F92EE;'>#Claudin 18.2#</a>，FGFR, BCMA, GPC3, Mesothelin, <a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>; 血液肿瘤包括CD19, CD7等, objectTitle=梅斯盘点：10类23种不限癌种的抗肿瘤类药物, objectType=article, longId=744128, objectId=21a5e4412876, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221009/f3030c9f9187475299543971eaaf09a9.jpg, objectUrl=/article/show_article.do?id=21a5e4412876, replyNumber=0, likeNumber=268, createdTime=2022-10-20, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21a5e4412876, moduleTitle=梅斯盘点：10类23种不限癌种的抗肿瘤类药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21a5e4412876)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1533968, encodeId=5220153396888, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=295679, objectId=7f802956e901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f802956e901, replyNumber=0, likeNumber=0, createdTime=2022-02-17, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f802956e901, moduleTitle=Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f802956e901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533967, encodeId=ab64153396e81, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, objectType=article, longId=207818, objectId=f15320e81875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f15320e81875, replyNumber=0, likeNumber=120, createdTime=2021-03-04, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f15320e81875, moduleTitle=JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f15320e81875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533966, encodeId=443c15339669f, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％, objectType=article, longId=206520, objectId=2862206520fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2862206520fd, replyNumber=0, likeNumber=88, createdTime=2021-02-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2862206520fd, moduleTitle=Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2862206520fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533965, encodeId=cecb1533965cb, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=Clini Cancer Research：二代ROS1-TKI，repotrectinib，治疗初治或ROS1突变的NSCLC, objectType=article, longId=197063, objectId=3fa819e06301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fa819e06301, replyNumber=0, likeNumber=132, createdTime=2020-07-06, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fa819e06301, moduleTitle=Clini Cancer Research：二代ROS1-TKI，repotrectinib，治疗初治或ROS1突变的NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fa819e06301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533964, encodeId=656d153396470, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=ARCH PATHOL LAB MED：肺腺癌患者检测ROS1免疫组化与ROS1融合状态意义？, objectType=article, longId=196458, objectId=0cdf19645858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cdf19645858, replyNumber=0, likeNumber=105, createdTime=2020-06-26, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cdf19645858, moduleTitle=ARCH PATHOL LAB MED：肺腺癌患者检测ROS1免疫组化与ROS1融合状态意义？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cdf19645858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533963, encodeId=776f153396372, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者, objectType=article, longId=195930, objectId=68ef19593022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68ef19593022, replyNumber=0, likeNumber=127, createdTime=2020-06-17, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68ef19593022, moduleTitle=NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68ef19593022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533962, encodeId=28141533962bb, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=精准医疗的突破：FoundationOne CDx癌症基因组谱可用于Rozlytrek治疗ROS1阳性肺癌的伴随诊断, objectType=article, longId=185334, objectId=f8d0185334ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d0185334ad, replyNumber=0, likeNumber=109, createdTime=2019-12-29, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d0185334ad, moduleTitle=精准医疗的突破：FoundationOne CDx癌症基因组谱可用于Rozlytrek治疗ROS1阳性肺癌的伴随诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8d0185334ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533961, encodeId=54841533961c6, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=Lancet Oncol：劳拉替尼治疗ROS1阳性的晚期NSCLC, objectType=article, longId=182127, objectId=ae9218212e1b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae9218212e1b, replyNumber=0, likeNumber=96, createdTime=2019-10-31, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae9218212e1b, moduleTitle=Lancet Oncol：劳拉替尼治疗ROS1阳性的晚期NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae9218212e1b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533960, encodeId=cb7415339605f, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, objectType=article, longId=177801, objectId=78401e780141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78401e780141, replyNumber=0, likeNumber=120, createdTime=2019-08-18, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78401e780141, moduleTitle=罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78401e780141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533959, encodeId=8a981533959f7, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=罗氏推出体外针对ROS1突变非小细胞肺癌的诊断测试, objectType=article, longId=168065, objectId=6e2b168065fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e2b168065fc, replyNumber=0, likeNumber=114, createdTime=2019-06-12, rootId=0, userName=wwzzly, userId=2f0712501452, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e2b168065fc, moduleTitle=罗氏推出体外针对ROS1突变非小细胞肺癌的诊断测试, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e2b168065fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533958, encodeId=8e0d153395827, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=ROS1重排NSCLC患者一线治疗如何选择？靶向抑或化疗？, objectType=article, longId=167951, objectId=682516e951d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=682516e951d1, replyNumber=0, likeNumber=122, createdTime=2019-06-11, rootId=0, userName=wwzzly, userId=2f0712501452, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=682516e951d1, moduleTitle=ROS1重排NSCLC患者一线治疗如何选择？靶向抑或化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=682516e951d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533957, encodeId=fbdd153395e0a, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南, objectType=article, longId=138096, objectId=5134138096d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5134138096d4, replyNumber=0, likeNumber=101, createdTime=2018-05-15, rootId=0, userName=wwzzly, userId=2f0712501452, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5134138096d4, moduleTitle=中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5134138096d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533956, encodeId=0c30153395645, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=ROS1阳性非小细胞肺癌诊断病理专家共识, objectType=article, longId=136615, objectId=e43613661584, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e43613661584, replyNumber=0, likeNumber=91, createdTime=2018-04-28, rootId=0, userName=wwzzly, userId=2f0712501452, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e43613661584, moduleTitle=ROS1阳性非小细胞肺癌诊断病理专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e43613661584)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533955, encodeId=3caf1533955d9, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=Lancet Oncol：Lorlatinib治疗ALK或ROS1重排的非小细胞肺癌, objectType=article, longId=117431, objectId=b55411e431ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b55411e431ee, replyNumber=0, likeNumber=92, createdTime=2017-10-26, rootId=0, userName=wwzzly, userId=2f0712501452, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b55411e431ee, moduleTitle=Lancet Oncol：Lorlatinib治疗ALK或ROS1重排的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b55411e431ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533954, encodeId=36801533954fc, content=<a href='/topic/show?id=0717156309a' target=_blank style='color:#2F92EE;'>#ROS1#</a>, objectTitle=克唑替尼治疗有脑转移的进展期ROS1阳性NSCLC患者的临床疗效结果公布, objectType=article, longId=116746, objectId=50e2116e46bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50e2116e46bc, replyNumber=0, likeNumber=102, createdTime=2017-10-20, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50e2116e46bc, moduleTitle=克唑替尼治疗有脑转移的进展期ROS1阳性NSCLC患者的临床疗效结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50e2116e46bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ROS1

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #EGFR# #靶向治疗# #ROS1#

为啥基因检测重复做？EGFR/HER2/MET和ROS1变异晚期肺癌治疗长达7年，ROS1融合出现又消失

2024-07-30发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #ROS1# #瑞波替尼#

NEJM：瑞波替尼在ROS1融合阳性非小细胞肺癌中的应用

2024-01-19发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#ROS1# #ROS1阳性肺癌# #信达生物# #泰莱替尼# #葆元医药#

新一代强效ROS1抑制剂泰莱替尼（AB-106）获优先审评资格！cORR高达92.5%

2023-12-23发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #ROS1# #间变性淋巴瘤激酶# #免疫组织化学# #荧光原位杂交#

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE：免疫组织化学和荧光原位杂交在检测非小细胞肺癌中间变性淋巴瘤激酶和ROS1基因重组方面的一致性

2023-12-07发表于上海

lifestar (审核中...)

前往app查看评论内容

全文收起在以往的认知里，#靶向#药、免疫治疗药是特定癌种、特定基因突变、特定靶点、特定通路才能用的药。不少患者基因检测结果没有理想的靶点，失去用药机会，或者尝试跨适应症用药，但跨适应症无法报销或申请赠药。现在，#泛癌种#广谱抗癌药（也称不限癌种的抗肿瘤类药物）的研发成功和上市，给了大家新希望！打破癌种限制让更多患者有药可用！这种不不好用癌种的治疗策略，也被称为“精准治疗”，主要源于#基因检测#的结果。根据基因检测的结果，一旦发现对应的靶点，就可以使用某个对应的#靶向治疗#药物。靶点检测最初从乳腺癌和肺癌比较常见，目前逐步向所有的癌种扩展，包括#卵巢癌#，#胃癌#等。例如，#非小细胞肺癌#患者要检测 #EGFR#、ROS1以及ALK，#乳腺癌#患者要检测HER2，胃癌患者要检测HER2。但是，相比起数百种之多的癌症驱动基因，每一类癌症当中，能够被应用于治疗的基因突变还是太少了，远不能满足所有患者的需求。而且目前有靶点的药物的类别也仍然有限，#实体瘤#主要包括PD-1/PD-L1，#EGFR#，#ROS1#，RET，ALK，MET，BRAF V600E，#NTRK#，#BRCA1/2#，#KRAS#，MSI-H及dMMR，#Claudin 18.2#，FGFR, BCMA, GPC3, Mesothelin, #TP53#; 血液肿瘤包括CD19, CD7等

梅斯盘点：10类23种不限癌种的抗肿瘤类药物

2022-10-20

智者为医08 (审核中...)

前往app查看评论内容

#ROS1#

Target Oncol:真实世界探索Crizotinib（克唑替尼）治疗ROS1阳性晚期非小细胞肺癌（NSCLC）患者的疗效

2022-02-17

智者为医08 (审核中...)

前往app查看评论内容

#ROS1#

JCO：恩曲替尼治疗局部晚期或转移性ROS1融合阳性NSCLC总体安全有效，颅内ORR可达79.2%

2021-03-04

智者为医08 (审核中...)

前往app查看评论内容

#ROS1#

Repotrectinib治疗ROS1阳性非小细胞肺癌，ORR高达93％

2021-02-02

智者为医08 (审核中...)

前往app查看评论内容

#ROS1#

Clini Cancer Research：二代ROS1-TKI，repotrectinib，治疗初治或ROS1突变的NSCLC

2020-07-06

智者为医08 (审核中...)

前往app查看评论内容

#ROS1#

ARCH PATHOL LAB MED：肺腺癌患者检测ROS1免疫组化与ROS1融合状态意义？

2020-06-26

智者为医08 (审核中...)

前往app查看评论内容

#ROS1#

NICE支持罗氏的ALK抑制剂Rozlytrek，治疗ROS1阳性的非小细胞肺癌患者

2020-06-17

智者为医08 (审核中...)

前往app查看评论内容

#ROS1#

精准医疗的突破：FoundationOne CDx癌症基因组谱可用于Rozlytrek治疗ROS1阳性肺癌的伴随诊断

2019-12-29

智者为医08 (审核中...)

前往app查看评论内容

#ROS1#

Lancet Oncol：劳拉替尼治疗ROS1阳性的晚期NSCLC

2019-10-31

智者为医08 (审核中...)

前往app查看评论内容

#ROS1#

罗氏的ALK抑制剂Rozlytrek获得FDA批准治疗NTRK基因融合实体瘤和ROS1阳性NSCLC

2019-08-18

wwzzly (审核中...)

前往app查看评论内容

#ROS1#

罗氏推出体外针对ROS1突变非小细胞肺癌的诊断测试

2019-06-12

wwzzly (审核中...)

前往app查看评论内容

#ROS1#

ROS1重排NSCLC患者一线治疗如何选择？靶向抑或化疗？

2019-06-11

wwzzly (审核中...)

前往app查看评论内容

#ROS1#

中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南

2018-05-15

wwzzly (审核中...)

前往app查看评论内容

#ROS1#

ROS1阳性非小细胞肺癌诊断病理专家共识

2018-04-28

wwzzly (审核中...)

前往app查看评论内容

#ROS1#

Lancet Oncol：Lorlatinib治疗ALK或ROS1重排的非小细胞肺癌

2017-10-26

仁医06 (审核中...)

前往app查看评论内容

#ROS1#

克唑替尼治疗有脑转移的进展期ROS1阳性NSCLC患者的临床疗效结果公布

2017-10-20

科室
- - 订阅+
  - 更多科室
工具
服务